India’s nutraceutical market set to nearly double to $57 billion by 2030 on preventive health boom

India's health-conscious population is fueling a boom in the nutraceutical market, projected to nearly double to $55-57 billion by 2030. This shift towards preventive care, supported by e-commerce and government initiatives, sees the sector growing at an impressive 10.5% CAGR. While regulatory efforts are strengthening, challenges like consumer awareness and scientific validation persist, yet the industry is poised for significant expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Na4JrkL
via IFTTT

Read More

Health ministry proposes faster approvals for medical device manufacturing licences

The Union health ministry is proposing to significantly cut down the time taken to issue manufacturing licenses for medical devices. Aimed at boosting ease of doing business and ensuring quicker access to quality products, the amendments will reduce timelines for low to high-risk devices. For instance, Class B devices will see a reduction from 140 to 115 days, and high-risk Class C and D devices from 105 to 90 days.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O2VZyaD
via IFTTT

Read More

Strides Pharma sells majority stake in arm Pivot Path for Rs 100 crore

Strides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital and Vintage Classic. This strategic move aims to accelerate Pivot Path's growth by infusing Rs 50 crore for future expansion. Strides will retain a 19.95% stake, while the investors will hold 65.05%. The transaction values Pivot Path at Rs 230 crore post-money.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Th4cZFf
via IFTTT

Read More

Shelf-life norms for imported drugs may be relaxed to reduce wastage

India is set to revise rules for imported medicines, proposing a 12-month minimum residual shelf life instead of the current 60% rule. This aims to ease business and reduce wastage, particularly for drugs with longer expiry dates. However, biological and radiopharmaceutical products will retain the stricter 60% requirement due to public health concerns. Other quality and safety regulations remain unchanged.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wThKdeR
via IFTTT

Read More

Centre set to tighten oversight of pharma packaging materials

India is set to implement a mandatory registration for printed pharmaceutical packaging manufacturers to combat counterfeit drugs. This move follows seizures of fake weight-loss drugs and vaccines, revealing that genuine packaging materials were being diverted and misused abroad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jsBbCfL
via IFTTT

Read More

India's GLP-1 boom slows amid price war, weak retention

Initial excitement for India's generic weight-loss drugs is fading. Domestic manufacturers are lowering sales targets due to slower-than-expected prescriptions and patient retention. Unexpected price cuts from the innovator, coupled with the high cost of generics for Indian consumers, are impacting adoption. This has led to a wait-and-watch approach for upcoming launches, with a potential revival anticipated later in the fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5kmvBXf
via IFTTT

Read More

Eli Lilly launches cancer drug Tanstrive in India

The launch follows marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for patients with locally advanced or metastatic solid tumours with a rearranged during transfection (RET) gene, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IZDaN69
via IFTTT

Read More